Intravenous thrombolysis is the standard treatment for patients with acute ischemic stroke occurring within 3 hours of symptom onset (1) . The rigid time window (less than 3 hours) is restrictive, and for many reasons too few stroke patients receive intravenous thrombolytic treatment. In addition, the optimal approach for acute ischemic stroke patients who do not respond to intravenous thrombolysis is uncertain (2) . As a result of significant associated risk of cerebral hemorrhage, thrombolysis is not yet a universally accepted routine treatment for stroke, and remains the subject of intense debate and research (1) .
Intraarterial thrombolysis is another option. The PROACT II study has shown the efficacy of localized intraarterial thrombolysis (LIT) for ischemic stroke patients within a 6-hour window (3) . In a recent study, intraarterial thrombolysis therapy after full-dose intravenous recombinant tissue plasminogen activator (t-PA) in patients with persisting occlusion and/or lack of clinical improvement appeared safe, and recanalization was achieved in 72% and a favorable outcome in 55% (2) . The rationale for mechanical thrombolysis is to reduce the burden of the clot by thrombectomy or to enhance the efficacy of the thrombolytic effects by increasing the surface area of the clot. Various devices, ranging from microwires, snares, and balloons to retrieval devices, have been implemented in improving the efficacy of intraarterial thrombolysis.
In this issue of Acta Radiologica, DONG JOON KIM and colleagues (4) describe their experience of mechanical thrombolysis with adjuvant intraarterial urokinase (UK) for the treatment of hyperacute ischemic stroke patients. They reviewed 19 patients with hyperacute proximal middle cerebral artery (MCA) occlusions who were treated by a standardized protocol using simple microwires and microcatheters for mechanical thrombus disruption with adjuvant intraarterial UK. The registry included hyperacute stroke patients who had been treated by LIT therapy in the 3-6-hour time window or as rescue therapy for patients who presented within the 3-hour time window and full-dose intravenous t-PA did not show early improvement. Recanalization was achieved in 18 of 19 patients (94.7%). The time interval between initial thrombolysis and recanalization was 18-117 min, and the mean UK dose was 375,789 IU (range 130,000-580,000). Two patients (10.5%) developed symptomatic hemorrhage. Three patients died (mortality rate 15.8%). Median baseline NIHSS scores showed improvement from 17 to 10 at presentation and discharge, respectively. Three-month good outcome was noted in 11 of 19 patients (57.9%, modified Rankin scale [mRS] 0-2). In addition, the long-term outcome rate seemed to be better in the rescue therapy subgroup compared to the LIT-only subgroup. This is an important result since the prognosis of intravenous t-PA nonresponsive patients has been very poor (mortality up to 39%) (5) . This prospective, well-conducted, and careful study by Dr. KIM and his colleagues (4) is recommended reading.
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